Non-Toll-like receptor innate immune signaling

非 Toll 样受体先天免疫信号传导

基本信息

  • 批准号:
    7540386
  • 负责人:
  • 金额:
    $ 39.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-01-01 至 2012-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Innate immune receptors trigger inflammation, activate microbial killing mechanisms, and instruct the development of acquired immune responses. The Toll-like receptor (TLR) family of innate immune recognition receptors is currently the most completely described family of innate receptors. These receptors play crucial roles in recognizing a wide range of microbial products, trigger NF-(B activation and production of a host of cytokines and chemokines, and have been demonstrated to be essential for effective host defense against many pathogens. However, TLRs do not activate all innate host defenses, and additional "non-TLR" innate immune receptors trigger phagocytosis, activate antimicrobial killing mechanisms, shape the consequences of TLR signaling, and are likely equally essential for effective host defense. Currently very few of these non-TLR innate receptors have been defined. We have established the ¿-glucan receptor Dectin-1 as one model for non-TLR based innate immune recognition. This receptor triggers phagocytosis of ¿-glucan-containing particles (such as yeast) and activates production of antimicrobial reactive oxygen species. Dectin-1 signaling also collaborates with TLR signaling to orchestrate cellular cytokine and chemokine production. While TLR signaling is relatively well-understood and shares much in common with cytokine receptor signaling, we have discovered that Dectin-1 signaling shares much in common with antigen receptor signaling. Thus signaling pathways generally associated with acquired immunity including the Src/Syk and NFAT (Nuclear Factor of Activated T cells) pathways are activated in phagocytes upon exposure to zymosan or yeast. We will examine the hypothesis that innate immune activation of NFAT is an important component of inflammatory responses. In Aim 1 will define the mechanisms by which Dectin-1 and yeast activate Src family kinases and Syk in macrophages, dendritic cells, and neutrophils. In Aim 2 we will explore the mechanisms by which Dectin-1 activates NFAT and the consequences of NFAT activation on inflammatory responses in vitro. In Aim 3 we will define the effect of the role of Dectin-1 and NFAT signaling in innate and adaptive immune responses in vivo.
描述(由申请人提供):先天免疫受体触发炎症,激活微生物杀伤机制,并指导获得性免疫应答的发展。先天免疫识别受体的Toll样受体(TLR)家族是目前描述最完整的先天受体家族。这些受体在识别广泛的微生物产物、触发NF-β B活化和产生大量细胞因子和趋化因子方面起关键作用,并且已被证明是有效抵抗许多病原体的宿主防御所必需的。然而,TLR并不激活所有的先天宿主防御,并且另外的“非TLR”先天免疫受体触发吞噬作用,激活抗微生物杀伤机制,塑造TLR信号传导的结果,并且可能对于有效的宿主防御同样重要。目前,这些非TLR先天受体中很少有被定义。我们已经建立了葡聚糖受体Dectin-1作为一种基于非TLR的先天免疫识别模型。该受体触发含葡聚糖颗粒(如酵母)的吞噬作用,并激活抗微生物活性氧物质的产生。Dectin-1信号传导还与TLR信号传导合作来协调细胞细胞因子和趋化因子的产生。虽然TLR信号传导相对较好地理解并且与细胞因子受体信号传导有许多共同之处,但是我们已经发现Dectin-1信号传导与抗原受体信号传导有许多共同之处。因此,通常与获得性免疫相关的信号传导途径,包括Src/Syk和NFAT(活化T细胞的核因子)途径,在暴露于酵母聚糖或酵母时在吞噬细胞中被活化。我们将检验NFAT的先天免疫激活是炎症反应的重要组成部分这一假设。 目的1将定义Dectin-1和酵母激活巨噬细胞、树突状细胞和中性粒细胞中Src家族激酶和Syk的机制。在目标2中,我们将探索Dectin-1激活NFAT的机制以及NFAT激活对体外炎症反应的影响。在目标3中,我们将定义Dectin-1和NFAT信号传导在体内先天性和适应性免疫应答中的作用的效果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David M. Underhill其他文献

Peptidoglycan recognition by the innate immune system
先天免疫系统对肽聚糖的识别
  • DOI:
    10.1038/nri.2017.136
  • 发表时间:
    2018-01-02
  • 期刊:
  • 影响因子:
    60.900
  • 作者:
    Andrea J. Wolf;David M. Underhill
  • 通讯作者:
    David M. Underhill
PD19-01 EVALUATION OF THE VAGINAL MYCOBIOME IN ASYMPTOMATIC PRE-MENOPAUSAL WOMEN
  • DOI:
    10.1016/j.juro.2018.02.991
  • 发表时间:
    2018-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Victoria Scott;Jie Tang;Tiina Drell;Jaak Simm;Andres Salumets;Madis Metsis;David M. Underhill;A. Lenore Ackerman
  • 通讯作者:
    A. Lenore Ackerman
Non-protective immune imprint underlies failure of emStaphylococcus aureus/em IsdB vaccine
金黄色葡萄球菌 IsdB 疫苗失败的基础是非保护性免疫印记
  • DOI:
    10.1016/j.chom.2022.06.006
  • 发表时间:
    2022-08-10
  • 期刊:
  • 影响因子:
    18.700
  • 作者:
    Chih-Ming Tsai;J.R. Caldera;Irshad A. Hajam;Austin W.T. Chiang;Chih-Hsiung Tsai;Haining Li;María Lázaro Díez;Cesia Gonzalez;Desmond Trieu;Gislâine A. Martins;David M. Underhill;Moshe Arditi;Nathan E. Lewis;George Y. Liu
  • 通讯作者:
    George Y. Liu

David M. Underhill的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David M. Underhill', 18)}}的其他基金

Measuring Phagosomal Temperatures
测量吞噬体温度
  • 批准号:
    8698868
  • 财政年份:
    2014
  • 资助金额:
    $ 39.75万
  • 项目类别:
Measuring Phagosomal Temperatures
测量吞噬体温度
  • 批准号:
    8796150
  • 财政年份:
    2014
  • 资助金额:
    $ 39.75万
  • 项目类别:
Host immunity to commensal gut fungi
宿主对共生肠道真菌的免疫力
  • 批准号:
    8340682
  • 财政年份:
    2012
  • 资助金额:
    $ 39.75万
  • 项目类别:
Host immunity to commensal gut fungi
宿主对共生肠道真菌的免疫力
  • 批准号:
    8490371
  • 财政年份:
    2012
  • 资助金额:
    $ 39.75万
  • 项目类别:
Host immunity to commensal gut fungi
宿主对共生肠道真菌的免疫力
  • 批准号:
    9598612
  • 财政年份:
    2012
  • 资助金额:
    $ 39.75万
  • 项目类别:
Host immunity to commensal gut fungi
宿主对共生肠道真菌的免疫力
  • 批准号:
    8690040
  • 财政年份:
    2012
  • 资助金额:
    $ 39.75万
  • 项目类别:
Host immunity to commensal gut fungi
宿主对共生肠道真菌的免疫力
  • 批准号:
    10160894
  • 财政年份:
    2012
  • 资助金额:
    $ 39.75万
  • 项目类别:
Phagosomal targeting of CARD proteins
CARD 蛋白的吞噬体靶向
  • 批准号:
    8074174
  • 财政年份:
    2010
  • 资助金额:
    $ 39.75万
  • 项目类别:
Innate Immune Sensing of Bacterial Sugars
细菌糖的先天免疫感应
  • 批准号:
    8442856
  • 财政年份:
    2008
  • 资助金额:
    $ 39.75万
  • 项目类别:
Dectin-1 Signaling Mechanisms
Dectin-1 信号传导机制
  • 批准号:
    8629147
  • 财政年份:
    2008
  • 资助金额:
    $ 39.75万
  • 项目类别:

相似海外基金

Development of back bone vectors for chimeric antigen receptors against key molecules, CD47 and CD24, activating macrophages
开发针对关键分子 CD47 和 CD24 的嵌合抗原受体的骨干载体,激活巨噬细胞
  • 批准号:
    23K06728
  • 财政年份:
    2023
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CAREER: Engineering next-generation chimeric antigen receptors for cancer immunotherapy using phospho-proteomics
职业:利用磷酸蛋白质组学设计用于癌症免疫治疗的下一代嵌合抗原受体
  • 批准号:
    2145853
  • 财政年份:
    2022
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Continuing Grant
Construction of a drug discovery platform utilizing antigen receptors that regulate the quality of cancer immunity
利用调节癌症免疫质量的抗原受体构建药物发现平台
  • 批准号:
    22K06603
  • 财政年份:
    2022
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Engineering synthetic adhesion receptors to enhance the sensitivity of therapeutic chimeric antigen receptors
工程合成粘附受体以增强治疗性嵌合抗原受体的敏感性
  • 批准号:
    MR/W031353/1
  • 财政年份:
    2022
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Research Grant
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10701754
  • 财政年份:
    2022
  • 资助金额:
    $ 39.75万
  • 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10557760
  • 财政年份:
    2022
  • 资助金额:
    $ 39.75万
  • 项目类别:
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
调节性 T 细胞上的嵌合抗原受体作为自身免疫性疾病的治疗策略。
  • 批准号:
    437200
  • 财政年份:
    2020
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Studentship Programs
Molecualr imaging for development of chimeric antigen receptors (CARs) resistant to T cell exhaustion
用于开发抗 T 细胞耗竭的嵌合抗原受体 (CAR) 的分子成像
  • 批准号:
    20H03536
  • 财政年份:
    2020
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    10542442
  • 财政年份:
    2020
  • 资助金额:
    $ 39.75万
  • 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    9922602
  • 财政年份:
    2020
  • 资助金额:
    $ 39.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了